Literature DB >> 25170116

Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Daniel W Beury1, Katherine H Parker1, Maeva Nyandjo1, Pratima Sinha1, Kayla A Carter1, Suzanne Ostrand-Rosenberg2.   

Abstract

MDSC and macrophages are present in most solid tumors and are important drivers of immune suppression and inflammation. It is established that cross-talk between MDSC and macrophages impacts anti-tumor immunity; however, interactions between tumor cells and MDSC or macrophages are less well studied. To examine potential interactions between these cells, we studied the impact of MDSC, macrophages, and four murine tumor cell lines on each other, both in vitro and in vivo. We focused on IL-6, IL-10, IL-12, TNF-α, and NO, as these molecules are produced by macrophages, MDSC, and many tumor cells; are present in most solid tumors; and regulate inflammation. In vitro studies demonstrated that MDSC-produced IL-10 decreased macrophage IL-6 and TNF-α and increased NO. IL-6 indirectly regulated MDSC IL-10. Tumor cells increased MDSC IL-6 and vice versa. Tumor cells also increased macrophage IL-6 and NO and decreased macrophage TNF-α. Tumor cell-driven macrophage IL-6 was reduced by MDSC, and tumor cells and MDSC enhanced macrophage NO. In vivo analysis of solid tumors identified IL-6 and IL-10 as the dominant cytokines and demonstrated that these molecules were produced predominantly by stromal cells. These results suggest that inflammation within solid tumors is regulated by the ratio of tumor cells to MDSC and macrophages and that interactions of these cells have the potential to alter significantly the inflammatory milieu within the tumor microenvironment.
© 2014 Society for Leukocyte Biology.

Entities:  

Keywords:  IL-10; IL-6; cancer; cytokines; nitric oxide; tumor microenvironment

Mesh:

Substances:

Year:  2014        PMID: 25170116      PMCID: PMC4226789          DOI: 10.1189/jlb.3A0414-210R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  39 in total

1.  Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Authors:  Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

2.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.

Authors:  Stephanie K Bunt; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 3.  Interleukin-10 and the immune response against cancer: a counterpoint.

Authors:  Simone Mocellin; Francesco M Marincola; Howard A Young
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

4.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

5.  Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3.

Authors:  Claudia Niemand; Ariane Nimmesgern; Serge Haan; Patrick Fischer; Fred Schaper; Rolf Rossaint; Peter C Heinrich; Gerhard Müller-Newen
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

6.  IL-6 signaling promotes tumor growth in colorectal cancer.

Authors:  C Becker; M C Fantini; S Wirtz; A Nikolaev; H A Lehr; P R Galle; S Rose-John; M F Neurath
Journal:  Cell Cycle       Date:  2005-02-03       Impact factor: 4.534

Review 7.  Regulation of immune responses by L-arginine metabolism.

Authors:  Vincenzo Bronte; Paola Zanovello
Journal:  Nat Rev Immunol       Date:  2005-08       Impact factor: 53.106

8.  Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages.

Authors:  Pooran Qasimi; Andrew Ming-Lum; Ali Ghanipour; Christopher J Ong; Michael E Cox; James Ihle; Nicolas Cacalano; Akihiko Yoshimura; Alice L-F Mui
Journal:  J Biol Chem       Date:  2005-12-12       Impact factor: 5.157

9.  Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

10.  IL-10 up-regulates nitric oxide (NO) synthesis by lipopolysaccharide (LPS)-activated macrophages: improved control of Trypanosoma cruzi infection.

Authors:  F Jacobs; D Chaussabel; C Truyens; V Leclerq; Y Carlier; M Goldman; B Vray
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

View more
  76 in total

Review 1.  Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.

Authors:  Asha Jayakumar; Alfred L M Bothwell
Journal:  J Immunol       Date:  2019-09-01       Impact factor: 5.422

2.  Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa.

Authors:  Yichen Chen; Qiusheng Li; Xinye Li; Da Ma; Juan Fang; Liqun Luo; Xiangqi Liu; Xi Wang; Vivian Wai Yan Lui; Juan Xia; Bin Cheng; Zhi Wang
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

3.  Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

Authors:  Zhiwu Tan; Li Liu; Mei Sum Chiu; Ka-Wai Cheung; Chi Wing Yan; Zhe Yu; Boon Kiat Lee; Wan Liu; Kwan Man; Zhiwei Chen
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

4.  Granulocytic myeloid-derived suppressor cells from human cord blood modulate T-helper cell response towards an anti-inflammatory phenotype.

Authors:  Natascha Köstlin; Margit Vogelmann; Bärbel Spring; Julian Schwarz; Judith Feucht; Christoph Härtel; Thorsten W Orlikowsky; Christian F Poets; Christian Gille
Journal:  Immunology       Date:  2017-06-08       Impact factor: 7.397

5.  Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Authors:  Amy W Ku; Jason B Muhitch; Colin A Powers; Michael Diehl; Minhyung Kim; Daniel T Fisher; Anand P Sharda; Virginia K Clements; Kieran O'Loughlin; Hans Minderman; Michelle N Messmer; Jing Ma; Joseph J Skitzki; Douglas A Steeber; Bruce Walcheck; Suzanne Ostrand-Rosenberg; Scott I Abrams; Sharon S Evans
Journal:  Elife       Date:  2016-12-08       Impact factor: 8.140

6.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 7.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

8.  Tolerance and immune suppression in the tumor microenvironment.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  2015-09-30       Impact factor: 4.868

9.  Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment.

Authors:  Lei Gong; Mauricio da Silva Caetano; Amber M Cumpian; Soudabeh Daliri; Alejandra Garza Flores; Seon Hee Chang; Cesar E Ochoa; Christopher M Evans; Zhentao Yu; Seyed Javad Moghaddam
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

Review 10.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.